title: High-dose methotrexate in osteosarcoma: let the questions surcease--time for final acceptance.
authors.affiliation: The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
authors.forename: Norman
authors.initials: N
authors.lastname: Jaffe
authors.forename: Richard
authors.initials: R
authors.lastname: Gorlick
mesh_terms: D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000188:drug therapy*; D002453:Cell Cycle / Q000187:drug effects; D002648:Child; D004334:Drug Administration Schedule; D006801:Humans; D007261:Infusions, Intra-Arterial; D007262:Infusions, Intravenous; D008175:Lung Neoplasms / Q000556:secondary; D008727:Methotrexate / Q000008:administration & dosage* / Q000009:adverse effects / Q000097:blood; D009846:Oliguria / Q000139:chemically induced; D012516:Osteosarcoma / Q000188:drug therapy* / Q000473:pathology / Q000556:secondary; D011379:Prognosis
chemical_list: D008727:Methotrexate